Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Serum panel

CR Cecilia Rademeyer
BK Bette Korber
MS Michael S. Seaman
EG Elena E. Giorgi
RT Ruwayhida Thebus
AR Alexander Robles
DS Daniel J. Sheward
KW Kshitij Wagh
JG Jetta Garrity
BC Brittany R. Carey
HG Hongmei Gao
KG Kelli M. Greene
HT Haili Tang
GB Gama P. Bandawe
JM Jinny C. Marais
TD Thabo E. Diphoko
PH Peter Hraber
NT Nancy Tumba
PM Penny L. Moore
GG Glenda E. Gray
JK James Kublin
MM M. Juliana McElrath
MV Marion Vermeulen
KM Keren Middelkoop
LB Linda-Gail Bekker
MH Michael Hoelscher
LM Leonard Maboko
JM Joseph Makhema
MR Merlin L. Robb
SK Salim Abdool Karim
QK Quarraisha Abdool Karim
JK Jerome H. Kim
BH Beatrice H. Hahn
FG Feng Gao
RS Ronald Swanstrom
LM Lynn Morris
DM David C. Montefiori
CW Carolyn Williamson
request Request a Protocol
ask Ask a question
Favorite

Fifty-four serum samples were collected from antiretroviral (ARV) drug-naïve, chronically HIV-1-infected individuals originating from 3 SAAVI (South African AIDS Vaccine Initiative) clinical trial sites in South Africa: Durban, Kwazulu-Natal (n = 16, CAPRISA); Cape Town, Western Cape (n = 20; Desmond Tutu HIV Foundation, DTHF); and Soweto, Gauteng (n = 18, Perinatal HIV Research Unit, PHRU) (S2 Table). Serum samples were pre-screened for potency and breadth against three clade C pseudoviruses (CAP8.6F, CAP255.16 and Du156.12), a clade C consensus (ConC), a clade B pseudovirus (6535), a clade B consensus (ConB) and a single clade A pseudovirus (Q23.17). From this, a panel of 30 sera was selected, 10 per site, representing differing breadth (selecting some low, medium and high) for assaying against the 200 Acute/Early clade C panel (S3 Table). Serum samples were collected between March 2011 and October 2013 and all were heterologous, except for two samples from Durban. All analyses were adjusted to correct for the inclusion of these autologous measurements.

Copyright and License information:  ©2016-07-19
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

0/150

tip Tips for asking effective questions

+ Description

Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.

post Post a Question
0 Q&A